This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: "CSPC Pharmaceutical Group" – news · newspapers · books · scholar · JSTOR (December 2018) (Learn how and when to remove this template message) This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. Please help improve it by replacing them with more appropriate citations to reliable, independent, third-party sources. (December 2018) (Learn how and when to remove this template message) A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. Please discuss further on the talk page. (December 2018) (Learn how and when to remove this template message) This article uses bare URLs, which are uninformative and vulnerable to link rot. Please consider converting them to full citations to ensure the article remains verifiable and maintains a consistent citation style. Several templates and tools are available to assist in formatting, such as reFill (documentation) and Citation bot (documentation). (September 2022) (Learn how and when to remove this template message) (Learn how and when to remove this template message)

CSPC Pharmaceutical Group (simplified Chinese: 石药集团有限公司; traditional Chinese: 石藥集團有限公司; pinyin: Shíyào jítuán yǒuxiàn gōngsī) (China Pharma, SEHK: 1093, Hang Seng Index component) researches, develops, manufactures and sells pharmaceutical products. Its headquarters is in China's Hebei Province.

CSPC produces both active pharmaceutical ingredient (API) and formulations. API products include penicillin, cefalosporins, synthetic vitamins, caffeine and ranitidine. Formulations include antibiotics, butylphthalide (NBP) and analgesics, in addition to nearly 1,000 other products.

CSPC's 15,000 employees are divided among more than ten subsidiaries, including CSPC Zhongrun, Weisheng, Zhongnuo and NBP.

CSPC Pharma's total assets are valued above RMB 8 billion. In 2007, CSPC Pharma achieved sales of RMB 8 billion and net income of RMB 485 million. Direct exports of US$300 million ranked CSPC first among China's pharmaceutical enterprises.[1]

One subsidiary, China Pharmaceutical Group Co., Ltd (China Pharma) is based in Hong Kong. It is listed on the Hang Seng China-Affiliated Corporations Index. In 2003 and 2004, China Pharma was listed as one of 100 excellent listed companies with turnover less than $1 billion.

CSPC Pharma is recognized as one of China's “500 Most Valuable Chinese Brands” and “Top 500 Chinese Enterprises.” In 2007, CSPC Pharma ranked second among China's top 100 pharmaceutical industry companies.[2]

See also

References

  1. ^ http://www.e-cspc.com/english/index.aspx
  2. ^ http://www.e-cspc.com/english/milestone.aspx

External links


Constituents of Hang Seng Index
Hang Seng China Enterprises Index companies of Hong Kong
Pharmaceutical companies of China
Categories